Towards Drug Repurposing in Cancer Cachexia: Potential Targets and Candidates was written by Santos, Joana M. O.;Costa, Alexandra C.;Dias, Tania R.;Satari, Setareh;Costa e Silva, Maria Paula;da Costa, Rui M. Gil;Medeiros, Rui. And the article was included in Pharmaceuticals in 2021.Recommanded Product: 1446817-84-0 This article mentions the following:
As a multifactorial and multiorgan syndrome, cancer cachexia is associated with decreased tolerance to antitumor treatments and increased morbidity and mortality rates. The current approaches for the treatment of this syndrome are not always effective and well established. Drug repurposing or repositioning consists of the investigation of pharmacol. components that are already available or in clin. trials for certain diseases and explores if they can be used for new indications. Its advantages comparing to de novo drugs development are the reduced amount of time spent and costs. In this paper, we selected drugs already available or in clin. trials for non-cachexia indications and that are related to the pathways and mol. components involved in the different phenotypes of cancer cachexia syndrome. Thus, we introduce known drugs as possible candidates for drug repurposing in the treatment of cancer-induced cachexia. In the experiment, the researchers used many compounds, for example, 1,1,1,3,3,3-Hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (cas: 1446817-84-0Recommanded Product: 1446817-84-0).
1,1,1,3,3,3-Hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate (cas: 1446817-84-0) belongs to piperazine derivatives. A form in which piperazine is commonly available industrially is as the hexahydrate, C4H10N2. 6H2O, which melts at 44 °C and boils at 125–130 °C. Intermediate for a wide range of pharmaceuticals, polymers, dyes, corrosion inhibitors, rubber accelerators and surfactants.Recommanded Product: 1446817-84-0
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics